Table 4.
Variable | All subjects n = 106 | Rheumatoid Arthritis n = 52 | Osteoarthritis n = 54 | ||||||
---|---|---|---|---|---|---|---|---|---|
Comorbidities and exercise | Presencea | Absencea | p-valueb | Presencea | Absencea | p-valueb | Presencea | Absencea | p-valueb |
Hypothyroidism | 65.99 (52) | 46 (34) | 0.019 | 77.59 (63) | 46.50 (33) | 0.169 | 65.99 (41) | 43 (37) | 0.058 |
Physical Activity | 43 (32) | 57.7 (36) | 0.055 | 42 (34) | 50 (35) | 0.179 | 43 (32) | 60.37 (40) | 0.177 |
Current treatment in rheumatoid arthritis patients | |||||||||
Variable | Presence a | Absence a | p -value b | - | - | - | |||
Current treatment with methotrexate | 44.5 (21) | 70.8 (56) | 0.013 | - | - | - | |||
Current treatment with other csDMARDs | 58.91 (43) | 39.5 (23) | 0.002 | - | - | - | |||
Current treatment with glucocorticoids | 46 (23) | 83.43 (57) | 0.054 | - | - | - | |||
Previous treatment with bDMARDs | 77.51 (48) | 45 (32) | 0.021 | ||||||
Current management in osteoarthritis patients | |||||||||
Follow-up by Physical and Rehabilitation medicine | 43 (24) | 56.5 (39) | 0,018 | - | - | - |
Median (Interquartile range);
U mann Withney; bDMARDS, biological disease-modifying antirheumatic drugs; csDMARDS, conventional synthetic disease-modifying antirheumatic drugs.